Exploiting the mechanical effects of ultrasound for noninvasive therapy

MA O'Reilly - Science, 2024 - science.org
Focused ultrasound is a platform technology capable of eliciting a wide range of biological
responses with high spatial precision deep within the body. Although focused ultrasound is …

[HTML][HTML] Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Sco** Review

SI Papacocea, D Vrinceanu, M Dumitru… - International Journal of …, 2024 - mdpi.com
Glioblastoma (GBM) is one of the most aggressive malignant tumors of the brain. We
queried PubMed for articles about molecular predictor markers in GBM. This sco** review …

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

E Catanzaro, M Beltrán-Visiedo, L Galluzzi… - Cellular & Molecular …, 2024 - nature.com
While immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the
clinical management of various malignancies, a large fraction of patients are refractory to …

A thermo-responsive chemically crosslinked long-term-release chitosan hydrogel system increases the efficiency of synergy chemo-immunotherapy in treating brain …

SH Chuang, KJ Chen, YT Cheng, YS Chen… - International Journal of …, 2024 - Elsevier
Glioblastoma multiforme (GBM) is an aggressive and common brain tumor. The blood-brain
barrier prevents several treatments from reaching the tumor. This study proposes a Chemo …

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: a novel combinatorial immunotherapy regimen for gliomas

KS Kim, K Habashy, A Gould, J Zhao, H Najem… - Neuro …, 2024 - academic.oup.com
Background Glioblastoma is a highly aggressive brain cancer that is resistant to
conventional immunotherapy strategies. Botensilimab, an Fc-enhanced anti-CTLA-4 …

The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells

F Di Cintio, M Argenziano, A Scomparin, S Capolla… - …, 2025 - Taylor & Francis
Background Recently, we developed AT101, an IgM-class mouse monoclonal antibody
directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target …

[HTML][HTML] Revolutionizing drug delivery: low-intensity pulsed ultrasound (LIPUS)-driven deep penetration into hypoxic tumor microenvironments of cholangiocarcinoma

S Hong, J Kim, G Chung, D Lee, JM Song - Theranostics, 2025 - pmc.ncbi.nlm.nih.gov
Background: Hypoxia is a major obstacle in the treatment of solid tumors because it causes
immune escape and therapeutic resistance. Drug penetration into the hypoxic regions of …

Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions

A Badani, A Ozair, M Khasraw, GF Woodworth… - Journal of neuro …, 2024 - Springer
Glioblastoma (GBM), the most common and aggressive primary central nervous system
(CNS) tumor in adults, continues to have a dismal prognosis. Across hundreds of clinical …

pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma

JL Meng, ZX Dong, YR Chen, MH Lin, YC Liu… - ACS …, 2025 - ACS Publications
The blood–brain barrier (BBB) remains a major obstacle for effective delivery of therapeutics
to treat central nervous system (CNS) disorders. Although transferrin receptor (TfR) …

[HTML][HTML] The Mechanism and Latest Research Progress of Blood–Brain Barrier Breakthrough

F Wang, L Qi, Z Zhang, H Duan, Y Wang, K Zhang, J Li - Biomedicines, 2024 - mdpi.com
The bloodstream and the central nervous system (CNS) are separated by the blood–brain
barrier (BBB), an intricate network of blood vessels. Its main role is to regulate the …